374 Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors

✍ Scribed by A. Awada; N. Houedé; J.P. Delord; M. Dubuisson; A. Italiano; Y. Bergé; S. Faivre; A. Taama; C. Lüpfert; E. Raymond

• Book ID: 119603057
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 46 KB
• Volume: 8
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(10)72081-4